TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06750367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Klapp method exercises
Description: The researcher will administer Klapp method exercises to the participant for a period of 1 month (twice in a week for 50 min .The researcher will perform stretching of upper limb, neck and thoracic region to the participants as a baseline treatment. Klapps exercises program include four point walk followed by two point walk and back walk, breathing exercise from kneeling position, breathing exercise from quadrapedal position, simple bounce glide with simulanteos breathing, bunny hop greeting. Each exercise will be performed with 10 repetitions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: At-Home exercise program
Description: theywill begiven printed information on an at-home exercise program, such corrective exercises (Chin tuck, stretchingof neck extensormuscles andpectoral musclegroups instandingandsupinepositions) (16) ,posturecorrection exercises(Thisexerciseprogramconsistedof2strengthening(of thedeep cervical flexorsandshoulderretractors)(26) ,andbreathingexercises(Deep breathing is an exercise that can regulate breathing patterns and improve posture. The deep breathing that is done repeatedly can overcome stiffness in the thoracic cage and straighten the curve of thoracic kyphosis)(27).Theywillbeaskedtoperformtheperiodof1month twiceinaweekfor50minwith10repetitionsofeachexercise.
Study: NCT06749795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIV001
Description: Orally administered for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered for 8 weeks
Study: NCT06750874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: One day workshop + telephone booster
Study: NCT06747520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-26HCl
Description: The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-26HCl
Description: The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-26HCl
Description: The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
Study: NCT06748274

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial Magnetic Stimulation (TMS) is a sophisticated neuromodulation technique that involves the use of a magnetic coil placed against the scalp to generate brief magnetic pulses. These pulses induce electric currents in the cortical neurons, leading to depolarization or hyperpolarization depending on the parameters of the stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial Magnetic Stimulation (TMS) is a sophisticated neuromodulation technique that involves the use of a magnetic coil placed against the scalp to generate brief magnetic pulses. These pulses induce electric currents in the cortical neurons, leading to depolarization or hyperpolarization depending on the parameters of the stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial Magnetic Stimulation (TMS) is a sophisticated neuromodulation technique that involves the use of a magnetic coil placed against the scalp to generate brief magnetic pulses. These pulses induce electric currents in the cortical neurons, leading to depolarization or hyperpolarization depending on the parameters of the stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial Magnetic Stimulation (TMS) is a sophisticated neuromodulation technique that involves the use of a magnetic coil placed against the scalp to generate brief magnetic pulses. These pulses induce electric currents in the cortical neurons, leading to depolarization or hyperpolarization depending on the parameters of the stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS)
Description: Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation technique that involves applying a low-intensity electrical current to specific areas of the scalp. The electric current induces alterations in the membrane potentials of underlying neuronal networks. The application of tDCS with concentric ring electrodes is a more targeted form of tDCS, allowing for more precise modulation of cortical activity compared to traditional tDCS methods.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition transcranial direct current stimulation (HD-tDCS)
Description: Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation technique that involves applying a low-intensity electrical current to specific areas of the scalp. The electric current induces alterations in the membrane potentials of underlying neuronal networks. The application of tDCS with concentric ring electrodes is a more targeted form of tDCS, allowing for more precise modulation of cortical activity compared to traditional tDCS methods.
Study: NCT06748157

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardiaCare RR2
Description: CardiaCare has developed a wrist band that delivers non-invasive neuromodulation to the median nerve to elicit a vagal response (Median-Vagus nerve stimulation-mVNS). The device is in the post-prototype development stage and is ready for human clinical trials. The CardiaCare RR2 device has already been approved by the IRB of the Chaim Sheba Medical Center, IL and the IL MOH (Ministry of Health) in an already completed pilot clinical trial for modulating AF.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham device will be dispensed, which will create a sensation but not provide therapy
Study: NCT06750796

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Half Swaddling Application
Description: Half swaddling application in term babies
Study: NCT06748313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango Pickle (Water-Based)
Description: The ingredients used in Mango Pickle (Water-based) are Raw mangoes, Carrots, Lemon, Green chili, Gum Berry (Lasora), Grewia asiatica (Phalsa), Sea salt, Fenugreek seeds whole, Fenugreek mashed, Fennel seeds, Chili flakes, Coriander seeds, Turmeric powder, Cumin, Black seeds, Bay leaves, Mashed garlic, Mustard oil, Vinegar, and Water. The pickle's fermentation process will be completed in 6-7 days, and it will be ready to use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango Pickle (Oil Based)
Description: The ingredients used in Mango Pickle (Oil-based) are Raw mangoes, Carrots, Lemon, Green chili, Gum Berry (Lasora), Grewia asiatica (Phalsa), Sea salt, Fenugreek seeds whole, Fenugreek mashed, Fennel seeds, Chili flakes, Coriander seeds, Turmeric powder, Cumin, Black seeds, Bay leaves, Vinegar, Mashed garlic, and Mustard oil. The pickle's fermentation process will be completed in 6-7 days, and it will be ready to use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carrot Pickle (Water-Based)
Description: The ingredients used in Carrot Pickle (Water-Based) are Carrots, Spring garlic, Turmeric, water, mashed mustard seeds, chili powder, salt, and Mustard oil. The pickle's fermentation process will be completed in 2-3 days, and it will be ready to use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radish Pickle (Water-Based)
Description: The ingredients used in Radish Pickle (Water-Based) are Radish, Spring garlic, Turmeric, water, mashed mustard seeds, chili powder, salt, and Mustard oil. The pickle's fermentation process will be completed in 2-3 days, and it will be ready to use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onion Pickle (Water-Based)
Description: The ingredients used in Onion Pickle (Water-Based) are Onion, Vinegar, Turmeric, water, mashed mustard seeds, chili powder, salt, and Mustard oil. The pickle's fermentation process will be completed in 3-4 days, and it will be ready to use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lemon & Chili Pickle (Water-Based)
Description: The ingredients used in Lemon \& Chili Pickle (Water-Based) are Lemon, Green Chili, Turmeric, Vinegar, water, and salt. The pickle's fermentation process will be completed in 2-3 days, and it will be ready to use.
Study: NCT06749236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test formulation(T) 200 mg deuteriumremidvir hydrobromide for suspension
Description: Participants will receive a single dose of the test formulation(T) (one bag of 200 mg deuteriumremidvir hydrobromide for suspension).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test formulation(T) 200 mg deuteriumremidvir hydrobromide for suspension
Description: Participants will receive a single dose of the test formulation(T) (one bag of 200 mg deuteriumremidvir hydrobromide for suspension).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference formulation(R) 100 mg deuteriumremidvir hydrobromide for suspension
Description: Participants will receive a single dose of the reference formulation(R) ( two bags of 100 mg deuteriumremidvir hydrobromide for suspension).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference formulation(R) 100 mg deuteriumremidvir hydrobromide for suspension
Description: Participants will receive a single dose of the reference formulation(R) ( two bags of 100 mg deuteriumremidvir hydrobromide for suspension).
Study: NCT06749925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: This intervention distinguishes itself from others by utilizing allogeneic dendritic cells derived from healthy donors fused with autologous tumor cells from patients, which is a novel approach compared to the commonly used autologous DC-based vaccines (DCVax).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Recent findings have shown that the anti-PD1 monoclonal antibody, a checkpoint inhibitor, can sustainably enhance the anti-tumor immune response. In this study, all patients in the intervention group (vaccine) who reach the fifth dose will be randomized to receive either pembrolizumab or a placebo as an addition to the experimental treatment regimen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this study, all patients in the intervention group (vaccine) who reach the fifth dose will be randomized to receive either pembrolizumab or a placebo as an addition to the experimental treatment regimen.
Study: NCT06748118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trained healthcare professionals deliver a simple, standardized and redundant 3-point message to patients, based on the levers of action for therapeutic adherence.
Description: This message is delivered with the aim of modifying the patient's behavior with regard to treatment intake. The research does not anticipate any change in the patient's medical prescriptions.
Study: NCT06749899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: QL1706 5mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
Study: NCT06749821

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape
Description: Kinesio tape (KT) is an elastic therapeutic tape used to treat sports injuries and various other disorders. It was first used by Dr. Kenzo Kase in 1979 to relieve pain and promote healing in soft tissues and is a method that is constantly being updated. The KT method is a therapeutic taping technique that relieves pain and facilitates lymphatic drainage by microscopically lifting the skin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tape (Arm 1)
Description: In this application, taping was applied in the same way but with a plaster tape.

Intervention type: OTHER
Group type: OTHER
Intervention: Control (no last irrigation)
Description: No application was made.
Study: NCT06748261

Intervention type: DIAGNOSTIC_TEST
Intervention: CCTAI model
Description: Using a derivative sub-cohort, the investigators aim to first develop an CCTA-based AI-assisted (CCTAI) screening model to distinguish patients with cardiac abnormalities from those normal controls. Second, the investigators target at developing a CCTAI diagnostic model with multi-classification output of cardiomyopathy diagnosis. Both models will be tested in internal validation cohort and external validation cohort.

Intervention type: DIAGNOSTIC_TEST
Intervention: CCTAI model
Description: Using a derivative sub-cohort, the investigators aim to first develop an CCTA-based AI-assisted (CCTAI) screening model to distinguish patients with cardiac abnormalities from those normal controls. Second, the investigators target at developing a CCTAI diagnostic model with multi-classification output of cardiomyopathy diagnosis. Both models will be tested in internal validation cohort and external validation cohort.
Study: NCT06748170

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ChatGPT
Description: OpenAI's ChatGPT language model with chat interface.
Study: NCT06748859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counterstrain technique
Description: In this group, participants will receive counterstrain technique on the Psoas major muscle and exercise training within two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: participants who will assign to this group will receive exercise therapy within two weeks.
Study: NCT06750393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Barre exercise along with gym ball exercises
Description: The Barre exercises will be administer to the participant of Group A for a period of 3 month.~Each exercise will be given for 10 s hold × 12 times/set × 3 sets/day × 3 days/week~× 12. Gym ball exercises program include Knee tucks, leg curls, back extension exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barre exercises
Description: The Barre exercises for a period of 3 month Each exercise will be given for 10 s hold × 12 times/set × 3 sets/day × 3 days/week~× 12. During
Study: NCT06751147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral Femoral Cutaneous Nerve Mobilization
Description: It consists of 24 patients who will be assessed by prone knee bend (PKB) test and knee range of motion will be measured by goniometer. Patients in this group will receive neural mobilization along with muscle energy techniques and conventional physical therapy. Neural mobilization will be performed on the patient while they will be lying on their side with the affected side facing up and their knee bent to a 90-degree angle. The therapist then extends and abducts the patient's hip while performing the procedure. The nerve stretch will be repeated five times, each time with a hold for 10 seconds, followed by a rest for 5 seconds
Study: NCT06749457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7760
Description: Participants will receive AZD7760 as a single intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7760
Description: Participants will receive AZD7760 as a single intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7760
Description: Participants will receive AZD7760 as a single intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7760
Description: Participants will receive AZD7760 as a single intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7760
Description: Participants will receive AZD7760 as a single intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered placebo through intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered placebo through intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered placebo through intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered placebo through intravenous infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered placebo through intravenous infusion.
Study: NCT06749080

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assist Reablement (including education and mentoring)
Description: Reablement on-line education will be standard and mandatory for both intervention groups. Mentoring will be formed according to the pre-requisites at the site.
Study: NCT05750407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle change
Description: Three modules target healthy eating, activity, and weight control behaviors
Study: NCT05530733

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pacifier
Description: Pacifiers produced for premature babies will be used in the study. Pacifiers will be made of silicone material suitable for premature baby health and will not contain any harmful substances. A separate pacifier will be used for each baby, and pacifiers will be sterilized before use.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pacifier
Description: Pacifiers produced for premature babies will be used in the study. Pacifiers will be made of silicone material suitable for premature baby health and will not contain any harmful substances. A separate pacifier will be used for each baby, and pacifiers will be sterilized before use.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Breast milk
Description: For babies assigned to the pacifier with breast milk group, their own breast milk will be applied by dripping 1 ml into the pacifier.
Study: NCT05641766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Participants will receive THC into a rapidly flowing IV infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Participants will receive an equivalent amount (about 1-2 ml) of placebo (sterile 190 proof USP ethanol). The placebo does not produce any measurable blood alcohol levels or subjective/behavioral effects.
Study: NCT05794581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-868
Description: CT-868

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as SC Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victoza
Description: Victoza as active comparator as SC Injection
Study: NCT04989803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KITE-363
Description: A single infusion of CAR-transduced autologous T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KITE-753
Description: A single infusion of CAR-transduced autologous T cells administered intravenously
Study: NCT06477107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix® 4x1HD-TDCS
Description: Is intended for inducing cortical neuromodulation for research and treatment purposes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix® 4x1HD-TDCS
Description: Is intended for inducing cortical neuromodulation for research and treatment purposes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix® 4x1HD-TDCS
Description: Is intended for inducing cortical neuromodulation for research and treatment purposes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix® 4x1HD-TDCS
Description: Is intended for inducing cortical neuromodulation for research and treatment purposes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix® 1x1 tDCS
Description: At-home remotely supervised transcranial direct current stimulation (tDCS) at an intensity of 2 mA for 20 minutes per session, with slow ramp-up and automatic turn off once it reaches the maximal intensity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix® 1x1 tDCS
Description: At-home remotely supervised transcranial direct current stimulation (tDCS) at an intensity of 2 mA for 20 minutes per session, with slow ramp-up and automatic turn off once it reaches the maximal intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training program
Description: Computerized cognitive therapy for 45 minutes per day that starts at the same time with stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training program
Description: Computerized cognitive therapy for 45 minutes per day that starts at the same time with stimulation
Study: NCT06278519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood, urinary and feces collection
Description: Blood, urinary and feces collection, at inclusion during acute phase of STEMI, and one year after inclusion visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Cardiac MRI at the acute phase of STEMI (Day 5 +/- 3) and at 1-year follow-up
Study: NCT05833789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Flexible Endoscope (MFE)
Description: After colonoscopy has been completed with the legacy colonoscope, the MFE will be introduced into the colon and traverse from the rectum to the cecum.